Compare BridgeBio Pharma Inc (BBIO) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Walmart Stores Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Walmart Stores Inc trades at $113.11 (market cap $896.56B). The key difference: Walmart Stores Inc is far larger — about 54× BridgeBio Pharma Inc's market cap, and Walmart Stores Inc pays a 0.88% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WMT | |
|---|---|---|
Market Cap | $16.61B | $896.56B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $134.20 |
52-Week Low | $47.29 | $96.05 |
Enterprise Value | $18.16B | $960.01B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Walmart (WMT) stock trades at $113.26, up 1.26% today, with a neutral technical signal and strong analyst consensus. The company demonstrates robust fundamentals with revenue growth to $681.0B in 2025 and net income of $19.4B, alongside consistent earnings beats. Recent news highlights operational innovations like drone delivery expansion and AI tools, while maintaining a solid dividend.
Outlook remains positive with a $142 consensus price target, though risks include competitive pressures and margin sustainability. The stock presents a long-term opportunity given its defensive positioning and growth initiatives, but investors should monitor execution against Amazon and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
